Merck Reports Strong Q3 2020 Results: Keytruda Global Sales Reach $10.387 Billion Year-to-Date
MSD
Pharmaceutical R&D and Manufacturer
On October 27, Merck & Co., Inc. announced its financial results for the third quarter of 2020, with revenue reaching $12.551 billion, a year-on-year increase of 1%; pharmaceutical business revenue amounted to $11.320 billion, representing a 2% year-on-year growth. For the first three quarters of 2020, Merck & Co., Inc. reported cumulative revenue of $35.479 billion, reflecting a 1% year-on-year increase.
From the oncology perspective, MSD’s Keytruda generated sales of $3.715 billion in Q3 2020, representing a 21% increase; of this, U.S. revenue amounted to $2.2 billion, with indications other than lung cancer contributing approximately 50% of sales. Cumulative revenue for Keytruda in the first three quarters of 2020 reached $10.387 billion, a 31% increase. Furthermore, Lynparza (olaparib) and Lenvima (lenvatinib), developed through MSD’s deep strategic collaborations with AstraZeneca and Eisai, respectively, achieved growth rates of 58% and 29% in Q3 2020.
Gardasil/Gardasil 9 vaccine products have gradually begun to recover from the impact of COVID-19, with sales of $1.187 billion in Q3 2020, a year-on-year decrease of 10%. The cumulative revenue for the first three quarters of 2020 was $2.941 billion, representing a year-on-year decline of 2%.
Regionally, MSD’s revenue in China for the third quarter of 2020 amounted to $990 million, representing a 10% year-on-year increase. Cumulative revenue for the first three quarters of 2020 reached $2.646 billion, surpassing Japan to become MSD’s third-largest global market after the United States and the European Union.
In the development of COVID-19 therapeutics and vaccines, MSD disclosed in its financial report that it has initiated two pivotal Phase II/III clinical studies for Molnupiravir (MK-4482), an oral antiviral candidate developed in collaboration with Ridgeback Bio. One study plans to enroll 1,450 adult outpatients with COVID-19, while the other aims to recruit 1,300 adult inpatients with COVID-19. The vaccine candidate V591 has entered Phase I clinical trials, and V590 is poised to enter Phase I clinical trials.
Original Title:MSD’s Performance in the First Three Quarters of 2020: Revenue in China Reached $2.646 Billion, Global Sales of Keytruda Amounted to $10.387 Billion
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.
